Association between Thyroid Function and Postoperative Outcomes in Patients with Acute Coronary Syndrome after Treatment with PCI: A Retrospective Study
DOI:
https://doi.org/10.59958/hsf.7731Keywords:
serum FT3, thyroid stimulating hormone, acute coronary syndrome, percutaneous coronary interventionAbstract
Objective: This study aims to investigate the relationship between thyroid function and prognosis in acute coronary syndrome (ACS) patients after percutaneous coronary intervention (PCI). Methods: According to the thyroid function status of the patients at admission, they were divided into the euthyroid group (Group A), subclinical hyperthyroidism group (Group B), subclinical hypothyroidism group (Group C), and low T3 group (Group D). The clinical data of the four patient groups were compared. The logistic regression model was used to analyze the relationship between thyroid function and postoperative outcomes in patients with ACS undergoing PCI. Results: A total of 200 ACS patients who underwent PCI treatment in our hospital from January 2022 to October 2023 were selected as the research population. The incidences of subclinical hyperthyroidism, subclinical hypothyroidism, and low T3 syndrome were 17.00% (34/200), (36/200), and 29.50% (59/200), respectively. Univariate analysis of variance showed significant differences in age, diabetes, smoking history, systolic pressure and heart rate at admission, shock index, blood urea nitrogen (BUN), Cr, glucose (GLU), fibrinogen (FIB), glycosylated hemoglobin (HbA1c), creatine kinase isoenzyme (CK-MB), and CRP among all groups (p < 0.05). Thyroid function markers differed significantly across the groups (p < 0.001). Specifically, Group B exhibited the lowest thyroid stimulating hormone (TSH) levels (0.23 ± 0.09 mIU/L), whereas Group C displayed the highest (8.05 ± 3.72 mIU/L). Group D showed the lowest free triiodothyronine (FT3) levels (2.74 ± 0.51 pmol/L), and Group B had the highest free thyroxine (FT4) levels (16.31 ± 2.62 pmol/L). A significant difference in the incidences of cardiovascular death and heart failure was observed among the four groups (p < 0.05). Notably, Group D showed higher incidences of cardiovascular death (11.86%) and heart failure (50.85%). Similarly, at 1-year follow-up, a significant difference in the incidences of cardiovascular death and heart failure were found among the four groups (p < 0.05). Specially, Group D exhibited higher rates of cardiovascular death (15.25%) and heart failure (27.12%). Logistic regression analyses highlighted FT3 as a significant predictor of adverse events during hospitalization (OR = 0.335, 95% CI: 0.222–0.506, p < 0.001), while TSH emerged as an independent risk factor for adverse events during 1-year follow-up (OR = 1.136, 95% CI: 1.040–1.240, p = 0.005). Conclusion: Patients with ACS have a higher incidence of mild thyroid dysfunction. Compared with patients with euthyroid function, patients with low triiodothyronine (T3) syndrome have a worse prognosis after PCI treatment. Serum FT3 concentration and TSH can be used as predictors of poor prognosis in ACS patients.
References
Han K, Shi D, Yang L, Wang Z, Li Y, Gao F, et al. Prognostic value of systemic inflammatory response index in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Annals of Medicine. 2022; 54: 1667–1677.
Buccheri S, Capodanno D, James S, Angiolillo DJ. Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms. Expert Opinion on Drug Safety. 2019; 18: 1171–1189.
Arambam P, Kaul U, Ranjan P, Janardhanan R. Prognostic implications of thyroid hormone alterations in acute coronary syndrome-A systematic review. Indian Heart Journal. 2021; 73: 143–148.
Jabbar A, Ingoe L, Thomas H, Carey P, Junejo S, Addison C, et al. Prevalence, predictors and outcomes of thyroid dysfunction in patients with acute myocardial infarction: the ThyrAMI-1 study. Journal of Endocrinological Investigation. 2021; 44: 1209–1218.
Abdu FA, Mohammed AQ, Liu L, Zhang W, Yin G, Xu B, et al. Low Free Triiodothyronine as a Predictor of Poor Prognosis in Patients With Myocardial Infarction With Non-Obstructive Coronary Arteries. Frontiers in Endocrinology. 2021; 12: 681978.
Cao Q, Jiao Y, Yu T, Sun Z. Association between mild thyroid dysfunction and clinical outcome in acute coronary syndrome undergoing percutaneous coronary intervention. Cardiology Journal. 2020; 27: 262–271.
Tian XX, Zheng SF, Liu JE, Wu YY, Lin L, Chen HM, et al. Free Triiodothyronine Connected With Metabolic Changes in Patients With Coronary Artery Disease by Interacting With Other Functional Indicators. Frontiers in Molecular Biosciences. 2021; 8: 681955.
Rasool R, Unar A, Jafar TH, Chanihoon GQ, Mubeen B. A Role of Thyroid Hormones in Acute Myocardial Infarction: An Update. Current Cardiology Reviews. 2023; 19: e280422204209.
Senguttuvan NB, Reddy PMK, Shankar P, Abdulkader RS, Yallanki HP, Kumar A, et al. Trans-radial approach versus trans-femoral approach in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An updated meta-analysis of randomized controlled trials. PLoS ONE. 2022; 17: e0266709.
Zhuang Q, Shen C, Chen Y, Zhao X, Wei P, Sun J, et al. Association of high sensitive C-reactive protein with coronary heart disease: a Mendelian randomization study. BMC Medical Genetics. 2019; 20: 170.
Bergmark BA, Mathenge N, Merlini PA, Lawrence-Wright MB, Giugliano RP. Acute coronary syndromes. Lancet. 2022; 399: 1347–1358.
Rosário PWS, Calsolari MR. Subclinical Hypothyroidism with TSH>7 mIU/l and≤10 mIU/l and Coronary Artery Disease. Hormone and Metabolic Research. 2020; 52: 85–88.
Hajian-Tilaki K, Heidari B, Bakhtiari A. Triglyceride to high-density lipoprotein cholesterol and low-density lipoprotein cholestrol to high-density lipoprotein cholesterol ratios are predictors of cardiovascular risk in Iranian adults: Evidence from a population-based cross-sectional study. Caspian Journal of Internal Medicine. 2020; 11: 53–61.
Kimura K, Kimura T, Ishihara M, Nakagawa Y, Nakao K, Miyauchi K, et al. JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome. Circulation Journal. 2019; 83: 1085–1196.
Kong S, Chen C, Zheng G, Yao H, Li J, Ye H, et al. A Nomogram Based on Lactate to Predict Major Adverse Cardiovascular Events for Acute Coronary Syndrome after Percutaneous Coronary Intervention. 2021. (preprint)
Kong S, Chen C, Zheng G, Yao H, Li J, Ye H, et al. A prognostic nomogram for long-term major adverse cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention. BMC Cardiovascular Disorders. 2021; 21: 253.
Yu N, Wang L, Zeng Y, Zhao Y, Chen S, Pan H, et al. The Association of Thyroid Hormones with Coronary Atherosclerotic Severity in Euthyroid Patients. Hormone and Metabolic Research. 2022; 54: 12–19.
Gürdoğan M, Altay S, Korkmaz S, Kaya Ç, Zeybey U, Ebik M, et al. The Effect of Thyroid Stimulating Hormone Level Within the Reference Range on In-Hospital and Short-Term Prognosis in Acute Coronary Syndrome Patients. Medicina. 2019; 55: 175.
Yuan D, Zhang C, Jia S, Liu Y, Jiang L, Xu L, et al. Predictive value of free triiodothyronine (FT3) to free thyroxine (FT4) ratio in long-term outcomes of euthyroid patients with three-vessel coronary artery disease. Nutrition, Metabolism, and Cardiovascular Diseases. 2021; 31: 579–586.
Abdel-Moneim A, Gaber AM, Gouda S, Osama A, Othman SI, Allam G. Relationship of thyroid dysfunction with cardiovascular diseases: updated review on heart failure progression. Hormones. 2020; 19: 301–309.
Gencer B, Cappola AR, Rodondi N, Collet TH. Challenges in the Management of Atrial Fibrillation With Subclinical Hyperthyroidism. Frontiers in Endocrinology. 2022; 12: 795492.
Tomoda F, Takata M, Izumino K, Oh-hashi S, Ueno H, Iida H. Effects of erythropoietin treatment on thyroid dysfunction in hemodialysis patients with renal anemia. Nephron. 1994; 66: 307–311.
Adams KF, Jr, Patterson JH, Oren RM, Mehra MR, O'Connor CM, Piña IL, et al. Prospective assessment of the occurrence of anemia in patients with heart failure: results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry. American Heart Journal. 2009; 157: 926–932.
van Vliet NA, Bos MM, Thesing CS, Chaker L, Pietzner M, Houtman E, et al. BBMRI Metabolomics Consortium. Higher thyrotropin leads to unfavorable lipid profile and somewhat higher cardiovascular disease risk: evidence from multi-cohort Mendelian randomization and metabolomic profiling. BMC medicine. 2021; 19: 1–13.
Lerner RK, Gruber N, Pollak U. Congenital Heart Disease and Thyroid Dysfunction: Combination, Association, and Implication. World Journal for Pediatric & Congenital Heart Surgery. 2019; 10: 604–615.
Xiong H, Yan P, Huang Q, Shuai T, Liu J, Zhu L, et al. A prognostic role for non-thyroidal illness syndrome in chronic renal failure:a systematic review and meta-analysis. International Journal of Surgery. 2019; 70: 44–52.
Ni WC, Kong ST, Lin K, Huang YH, Li JF, Shi SL, et al. Normal thyroid stimulating hormone is associated with all-cause mortality in patients with acute myocardial infarction after percutaneous coronary intervention. European Journal of Medical Research. 2023; 28: 199.
Wang B, Liu S, Li L, Yao Q, Song R, Shao X, et al. Non-thyroidal illness syndrome in patients with cardiovascular diseases: A systematic review and meta-analysis. International Journal of Cardiology. 2017; 226: 1–10.
De Luca R, Davis PJ, Lin HY, Gionfra F, Percario ZA, Affabris E, et al. Thyroid Hormones Interaction With Immune Response, Inflammation and Non-thyroidal Illness Syndrome. Frontiers in Cell and Developmental Biology. 2021; 8: 614030.
Wang J, Zhang R. Evaluation of 99mTc-MIBI in thyroid gland imaging for the diagnosis of amiodarone-induced thyrotoxicosis. The British Journal of Radiology. 2017; 90: 20160836.
Published
How to Cite
Issue
Section
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
